Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$7.22 - $18.82 $397,822 - $1.04 Million
-55,100 Reduced 74.46%
18,900 $141,000
Q1 2024

May 15, 2024

BUY
$16.79 - $25.38 $322,368 - $487,296
19,200 Added 35.04%
74,000 $1.26 Million
Q4 2023

Feb 14, 2024

BUY
$12.21 - $23.36 $556,776 - $1.07 Million
45,600 Added 495.65%
54,800 $1.24 Million
Q3 2023

Nov 14, 2023

SELL
$11.84 - $18.65 $36,704 - $57,814
-3,100 Reduced 25.2%
9,200 $140,000
Q2 2023

Aug 14, 2023

SELL
$7.65 - $13.95 $70,380 - $128,340
-9,200 Reduced 42.79%
12,300 $158,000
Q1 2023

May 15, 2023

SELL
$7.08 - $12.62 $19,116 - $34,074
-2,700 Reduced 11.16%
21,500 $177,000
Q4 2022

Feb 14, 2023

SELL
$0.64 - $9.3 $37,760 - $548,700
-59,000 Reduced 70.91%
24,200 $223,000
Q3 2022

Nov 14, 2022

BUY
$0.63 - $2.05 $52,416 - $170,559
83,200 New
83,200 $54,000

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $131M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.